Why do BCL-2 inhibitors work and where should we use them in the clinic?
Montero J, Letai A. · 2018
Read Why do BCL-2 inhibitors work and where should we use them in the clinic? by Montero J, Letai A. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5729538.txt.
Introduction
Montero and Letai explain why drugs that block BCL-2 proteins can kill cancer cells. Cancer cells often lean on anti-death proteins to survive stress and treatment. That lean, once found, becomes a weak point. The review sets out how to measure a cell's readiness to die.
A test called BH3 profiling shows which survival protein a cancer depends on. A dynamic form of the test checks drug pairs before care is chosen. Such tests can match BH3 mimetic drugs to the right patients. The authors argue this path could make cancer care more personal.
Catalog record
| CREATOR | Montero J, Letai A. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Why do BCL-2 inhibitors work and where should we use them in the clinic? By Joan Montero, Antony Letai Published in: Cell Death and Differentiation DOI: 10.1038/cdd.2017.183 ABSTRACT Abstract Intrinsic apoptosis is controlled by the BCL-2 family of proteins but the complexity of intra-family interactions makes it challenging to predict cell fate via standard molecular biology techniques. We discuss BCL-2 family regulation and how to determine cells’ readiness for apoptosis and anti-apoptotic dependence. Cancer cells often adopt anti-apoptotic defense mechanisms in response to oncogenic stress or anti-cancer therapy. However, by determining their anti-apoptotic addiction, we can use novel BH3 mimetics to overwhelm this apoptotic blockade. We outline the development and uses of these unique anti-apoptotic inhibitors and how to possibly combine them with other anti-cancer agents using dynamic BH3 profiling (DBP) to improve personalized cancer treatment. FACTS - BCL-2 family proteins and their complex interactions regulate intrinsic apoptosis. - BH3 profiling can determine cancer cells’ priming for cell death and anti-apoptotic dependencies. - Cancer cells often acquire anti-apoptotic defense mechanisms against oncogenic stress and therapy. - The DBP functional assay can be used to determine effective combinations of anti-cancer agents with BH3 mimetics to improve cancer treatment. OPEN QUESTIONS - Is anti-apoptotic adaptation a common defense mechanism in most cancer types? - Can BH3 mimetics alone or in combination be used to treat solid tumors? - Will functional assays be able to guide BH3 mimetics’ use in the clinic? Programmed cell death (PCD) has been observed in many forms of life from metazoans to mammals. Perhaps the best studied PCD pathway, and the first characterized, is apoptosis. Kerr and collaborators first described apoptosis in the early 70s in mammalian tissue sections where they observed that dying cells showed stereotypic nuclear condensation and cellular fragmentation. Moreover, they found that these fragments were phagocytosed by nearby cells.1 These fragments, also known as apoptotic bodies, are the remains of the plasma membrane, containing cell fragments and presenting phosphatidylserine in their surface as an 'eat me signal' that can be recognized by phagocytic white blood cells.2 Two distinct pathways of apoptosis have been previously characterized: extrinsic and intrinsic. The extrinsic pathway occurs when specific receptors on the cell surface called death receptors are activated, such as TNFR, FAS (CD95) and DR3/WSL. Ligand binding to the receptor induces a change in the intracellular region that promotes adapter proteins activation and death-inducing signaling complex formation. Thus, initiator caspases, such as caspase-8, get cleaved and activated, resulting in initiation of downstream executioner caspases that orchestrate apoptosis. Active caspase-8 also can cleave and activate the BH3-only protein BID that can promote the intrinsic pathway, connecting both apoptotic modes.3 Intrinsic apoptosis, also referred as the mitochondrial pathway, is executed in response to cellular damage and most anti-cancer agents, and the B-cell lymphoma 2 or BCL-2 family proteins regulate it. These proteins control mitochondrial outer membrane permeabilization (MOMP), which for most instances can be considered the point of no return for apoptosis. This permeabilization allows the release of soluble proteins such as cytochrome c and SMAC/DIABLO, from the mitochondrial intermembrane space into the cytosol. Once these proteins are released, cytochrome c binds to APAF-1 and caspase-9 in presence of dATP to form the apoptosome, which activates downstream effector caspases and triggers apoptosis.4 BCL2: the family founder The founding member of the family, BCL-2 was identified as an oncogene resulting from a translocation between chromosomes 14 and 18 that promoted malignant lymphomagenesis.5, 6 In the early 90’s, several laboratories identified BCL-2 as a pro-survival protein that prevented apoptotic cell death and facilitated MYC-induced transformation.7, 8 The next obvious question at the time was: if BCL-2 protects from PCD, which proteins promote apoptosis? The answer came with the identification of a pro-death protein bound to BCL-2, named BCL-2-associated X or BAX, with similar structure and sequence homology to BCL-2.9 The other members of the so-called BCL-2 family were discovered in the following years based on protein interactions and their similar protein structure. They were classified as pro- or anti-apoptotic depending on their biological activity.10, 11, 12, 13 Following their identification, it became clear that MOMP and the release of cytochrome c was the triggering event of apoptosis and that BCL-2 prevented cell death by stopping this event.14, 15, 16, 17 The BCL2 family of pro-apoptotic and anti-apoptotic proteins The BCL-2 family proteins can be classified based on their structure and BCL-2 homology (BH) domains. The anti-apoptotic members BCL-2, BCL-XL, BCL-W, MCL-1 and A1/BFL-1 possess four BH domains, BH1-BH4, and present a hydrophobic groove in their structure that binds to the BH3 domain found in the pro-apoptotic. The pro-apoptotic effector proteins, BAX, BAK and BOK, possess three to four BH domains, and have the capacity to form pores in the mitochondrial outer membrane.18, 19, 20 These domains are composed of nine α-helices, including a transmembrane C-terminal α-helix that can anchor to the mitochondrial outer membrane. Their tridimensional structure are very similar to membrane pore-forming domains found in diphtheria toxin and colicins.21 There is a third group of proteins possessing only the BH3 domain, therefore named BH3-only proteins, with a pro-apoptotic function, including BIM, BID, PUMA, BAD, NOXA, HRK, BMF, BIK and others.13, 22, 23, 24, 25, 26, 27 Interaction between pro- and anti-apoptotic proteins takes place via the binding of the hydrophobic face of the amphipathic BH3 alpha-helix from the pro-apoptotic protein into a hydrophobic pocket in the anti-apoptotic protein formed by the BH1, BH2 and BH3 domains. Regulation of MOMP by the BCL-2 family of proteins Once they are activated, effector proteins BAX and BAK oligomerize in the mitochondrial outer membrane to promote MOMP and cytochrome c release.18, 19 In fact, a double knockout of BAX and BAK prevents apoptosis in response to most stimuli.28, 29 The third effector protein BOK may be regulated by protein stability and can induce MOMP in response to endoplasmic reticulum stress insults, and its activation may not rely on other BCL-2 family proteins.30 However, regulation of BOK remains a matter of uncertainty.31, 32 BAX and BAK oligomerization can be directly engaged by activator BH3-only proteins such as BIM13, 33 and BID,22 although showing specificity differences.34 Other BH3-only proteins have recently emerged as direct activators as well, such as PUMA and NOXA, although with less potency compared to BIM or BID.35, 36, 37, 38 The BH3 domains found in these BH3-only proteins induce an allosteric change in BAX and BAK that promotes the formation of high-ordered oligomers that form pores in the mitochondrial outer membrane to cause MOMP.39, 40, 41 The anti-apoptotic proteins, including BCL-2, BCL-XL, MCL-1, BCL-W and BFL-1/A1, can prevent MOMP and apoptosis by two complementary mechanisms. They can directly bind the BH3 domain of activator BH3-only proteins, preventing BAX and BAK oligomerization.42, 43, 44 On the other hand, they can directly bind the activated monomeric forms of BAX and BAK, whose conformational change induces BH3 domain exposure.45, 46, 47 The most potent activators’ BH3 domains, like BIM, BID (and PUMA), interact promiscuously with all anti-apoptotic proteins and can directly activate BAX and BAK. The sensitizers within the family and their mechanism of action There is a fourth group of BCL-2 family proteins possessing only a BH3 domain, the so-called sensitizers. Sensitizers can be considered